Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Gadolite® Oral Suspension' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadolite Oral Suspension' found in 0 term [] and 0 definition [], (+ 4 Boolean[] results
1 - 4 (of 4)     
Result Pages : [1]
MRI Resources 
Sequences - Spine MRI - Mobile MRI - Open Directory Project - Nerve Stimulator - Developers
 
Gadolite® Oral SuspensionInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
An oral suspension of synthetic crystalline aqueous orange-flavored MRI contrast agent to enhance delineation of the bowel. Gadolite contains gadolinium, a lanthanide metal with paramagnetic characteristics. The toxic Gd is bound to become inert, along with water, inside a zeolite crystalline lattice structure. Gadolite gives a bright signal, and provides improved definition of the gastrointestinal tract from adjacent tissues.
Pharmacyclics receives an approvable letter from the FDA for Gadolite® Oral Suspension and in the United Kingdom an European marketing agreement signed with E-Z-Em, Ltd. in Dec. 1996.
Drug Information and Specification
NAME OF COMPOUND
Gadolinium zeolite, Gadolinium chloride hexahydrate
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Paramagnetic
PHARMACOKINETIC
Gastrointestinal
PREPARATION
Oral suspension
INDICATION
Bowel marking
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Suspension
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada, Mexico, EU
Gadolite® Oral Suspension
for sale
spacer
 
• Share the entry 'Gadolite® Oral Suspension':  Facebook  Twitter  LinkedIn  
MRI Resources 
Case Studies - Directories - MR Myelography - Functional MRI - Education - Claustrophobia
 
Pharmacyclics, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.pcyc.com Pharmacyclics is a pharmaceutical company developing novel agents to improve current therapeutic approaches to cancer, cardiovascular diseases, and inflammation. The company's proprietary products are derived from its core technology in biometallic chemistry. These products under development are based upon small molecules, which bind metals in a unique way and are capable of capturing and focusing forms of energy used in a variety of medical applications. The company has one product in registration with the FDA, Gadolite® Oral Suspension, a contrast agent for imaging the gastrointestinal tract; two products in clinical development, Gd-Tex (Motexafin gadolinium), a radiation sensitizer, Lu-Tex, a photosensitizer; and several compounds in preclinical development.

MRI Contrast Agents:
Contact Information
MAIL
Pharmacyclics Inc.
995 East Arques Avenue
94085 Sunnyvale, California
USA
PHONE
+1-408-774-0330
FAX
+1-408-774-0340
spacer

• View the DATABASE results for 'Pharmacyclics, Inc.' (2).Open this link in a new window


• View the NEWS results for 'Pharmacyclics, Inc.' (5).Open this link in a new window.
 
Further Reading:
  News & More:
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday, 21 December 2007   by www.prnewswire.com    
Texaphyrin Compounds Visualize Vulnerable Plaque
Friday, 4 June 2004   by www.hospimedica.com    
MRI Resources 
Examinations - Societies - Stent - Distributors - Cochlear Implant - MRA
 
E-Z-EM, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.ezem.com [This entry is marked for removal.]

E-Z-EM, Inc. is headquartered in New York and develops, manufactures and markets diagnostic imaging products used by radiologists like the MRI bowel marker Gadolite® Oral Suspension.
In addition to medical diagnostics systems, the company's products include MR-compatible interventional devices, such as biopsy needles. E-Z-EM is also a third-party contract manufacturer of contrast media.
Bracco Diagnostics, Inc. , the US-based subsidiary of Bracco Imaging S.p.A. and part of the Bracco Group, announced in Oct. 2007 that it has entered into a merger agreement to acquire E-Z-EM, Inc. (NASDAQ: EZEM) for a total consideration of about $ 240 million. Upon completion of the procedure and subject to the approval of the regulatory authorities, Bracco Diagnostics Inc. will incorporate E-Z-EM.
Contact Information
MAIL
E-Z-EM, Inc.
Westbury, New York
USA
PHONE
+1-800-544-4624
CONTACT INFO PAGE
spacer

• View the NEWS results for 'E-Z-EM, Inc.' (1).Open this link in a new window.
MRI Resources 
Pregnancy - Fluorescence - Guidance - Breast Implant - MRI Training Courses - Education
 
Gadolinium ZeoliteInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(Gadolite® oral Suspension) An oral paramagnetic MRI contrast agent to enhance delineation of the bowel. Zeolites are hydrated aluminosilicates with large holes that can provide a temporary home for guest molecules like gadolinium. Zeolites modified with Gd (III) are effective positive MRI contrast agents for gastrointestinal application.
spacer

• View the DATABASE results for 'Gadolinium Zeolite' (3).Open this link in a new window

MRI Resources 
MRI Technician and Technologist Career - Spectroscopy pool - Colonography - Societies - Manufacturers - Shoulder MRI
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



New acceleration techniques will :
reduce scan times 
cause artifacts 
increase expenses 
be useful if you have a lot of experience 
doesn't do much 
never heard of 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 21 November 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]